New federal labeling guidelines for the abortion pill deliver a major victory to the abortion-rights movement, and throw opponents of the procedure on the defensive.
The emotional battle over abortion has been fought out before the Supreme Court, in state legislatures, and on Capitol Hill, but the Food and Drug Administration has just changed the terms of engagement.
The FDA’s decision this week to approve new labeling guidelines for medical abortion delivers a huge victory to the pro-choice movement, and robs pro-life advocates of a key tool for restricting access to the procedure. The action makes the abortion pill mifepristone more widely accessible and easier to administer to women seeking to terminate their pregnancies.
For more than a decade, public health advocates have urged the FDA to relax its labeling rules for mifepristone to bring them more in line with longstanding European practices and with obstetric recommendations. The new guidelines lengthen the window during which women may induce an abortion medically, from 49 to 70 days, and trim from three or four to two the number of trips women will have to make to a medical professional in most states. The new guidelines also permit a nurse practitioner to administer the drug….. Read more.
About Double take Sociology
I am a Professor of Sociology, a Research Associate in the Pepper Institute on Aging and Public Policy, and an Associate Dean for Faculty Development and Community Engagement in the College of Social Sciences and Public Policy at Florida State University. I research (and write about) social movements, mass media and politics. To find links to my research, visit www.DeanaRohlinger.com.